CAMBRIDGE, Mass., Nov. 6, 2026 /PRNewswire/ — Insilico Medicine, a clinical-stage generative AI drug discovery company, today announced the open-source release of Longevity Grok, the Personal Longevity Superintelligence (PLSI) and launched the website longevitygrok.si, in collaboration with leading geroscience researcher David Sinclair from Harvard Medical School. Developed for the Grok Bot platform, PLSI is an open-source, multi-agent AI system designed to unify fragmented personal health records, track biological analysis, formulate personalized lifestyle interventions, predict and score post-intervention biomarker changes, as well as drive communal AI-powered geroscience research.
For decades, health management and longevity medicine have been hampered by severe data fragmentation. Laboratory blood panels, continuous glucose monitoring, wearable streams, epigenetic assays, and clinical records sit across disconnected portals, leaving patients unable to follow their biological trajectory and clinicians working from incomplete histories. Modern healthcare turns to LLMs to close that gap, however, without persistent, auditable memory or follow-up on if advice actually improves outcomes, they rarely outperform traditional methods.
Personal Longevity Superintelligence (PLSI) addresses this gap with a continuous, 24/7 automated research loop. It converts fragmented medical data into a standardized longitudinal health trajectory and generates accountable, predictive guidance through a multi-agent architecture. The system continuously forecasts health risks, proposes interventions, and scores outcomes through closed-loop feedback.
Running within Grok Bot’s secure environment, it coordinates a team of up to 30 specialized AI agents, standardizes heterogeneous records with clinical coding systems such as LOINC, RxNorm, and UCUM, and uses always-on routines to monitor longevity science updates, organize incoming data, and keep the personal health state current without constant re-prompting. The same system is framed for three complementary roles:
As a personal longevity assistant, PLSI turns scattered labs, wearables, epigenetic assays, and clinical files into a unified, audit-ready health trajectory on the user’s device. It proposes lifestyle, nutritional, or longevity interventions with an auditable “prediction card” (target biomarker, confidence interval, time horizon, and evidence grade), evaluates each plan through an agent-driven adversarial review. When follow-up results arrive, PLSI scores whether outcomes fall within the predicted interval, confirms direction, and tracks calibration over time, turning each choice into a checkable N-of-1 experiment. Users can also voluntarily allocate unused daily token quota to Idle Research in the background to find new ways to increase their lifespan.
As a physician’s assistant, PLSI supplies structured longitudinal context instead of fragmented PDFs and portal exports. Standardized representations and a coherent biological trajectory help clinicians better organize their workflow Prediction cards and evidence grades aid in decision-making, while closed-loop scoring after follow-up supports auditable discussion of response and adherence. PLSI also features safeguards that overrule AI discretion to keep formal diagnosis and prescriptions solely with licensed physicians.
As a partner for aging research, PLSI extends individual tracking into communal discovery. Users may opt in to contribute consented, deidentified trajectories to Longevity Mothership via an anonymous relay with an irrevocable kill switch to purge records on demand. Idle Research is a modern take on volunteer computing platforms , such as Folding@home, which let autonomous researcher agents scan literature, formulate hypotheses, and design analyses based on public databases to accelerate target discovery and other anti-aging discovery activities.
Across all three roles, privacy is the default: a zero-trust architecture keeps raw medical files and identifiable clinical records in the user’s environment , unless the user explicitly opts into communal research. Both the PLSI Client and the Longevity Mothership backends are fully open-source and freely available on GitHub for review and contribution. Both setups feature data controller agents, which scrub the data at egress and intake points to prevent entry re-identification.
PLSI is available to all Grok Bot users and can be installed by instructing your bot with the following one-liner:
Set yourself up using https://github.com/Insilico-org/plsi
The agentic skills and code are provided as an open-source package which can be inspected and modified by all, according to their needs.
“Longevity Grok turns Grok Bot into an open platform where individuals, physicians, and scientists can use AI to better understand their health, predict the effects of interventions, and find ways to live longer, healthier lives,” said David A. Sinclair, Ph.D., Professor of Genetics and Co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. “What makes this exciting is that people can contribute to scientific discovery while improving their own health, helping us understand why we age and how we might slow or even reverse it.”
“Currently, there are zero tools that are clinically proven to give a healthy person an additional year of life if they are already dieting, exercising, sleeping, and getting regular diagnostics,” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine. “Longevity Grok is a distributed system designed around a personal research space where you can work with your own data to optimize your health, longevity, and peak-span trajectories. As this system diffuses into the community, we expect to achieve longevity superintelligence, enabling a vast network of individuals to conduct autonomous research on their own biology while utilizing shared computation resources to pursue advanced longevity experiments. Aging is the only inescapable constraint on human freedom, and pushing this frontier is about giving people the optionality to remain young, healthy, and productive for as long as possible.”
Longevity has been central to Insilico’s mission since its inception. The company’s path drew industry attention in 2015 at the NVIDIA GTC conference, where Alex Zhavoronkov, Ph.D., founder and CEO of Insilico, challenged the tech world with a provocative question: “Can NVIDIA cure aging?” In 2014, Insilico established the annual Aging Research and Drug Discovery (ARDD) meeting, now widely regarded as a leading academic gathering for geroscience and biogerontology. The 13th ARDD, held at Harvard University in 2026, brought together leading academic investigators, pharmaceutical executives, and clinical pioneers to translate longevity discoveries into actionable medicine.
In 2026, Insilico accelerated the translation of AI-driven longevity research from experimental theory to transformative biological interventions. In April, the company announced the industry’s first longevity board of high-profile scientists, chaired by Andrew Adams, Ph.D., Group Vice President of Molecular Discovery at Eli Lilly and Company, to advance AI-driven aging research for drug discovery. In September, Insilico open-sourced an AI longevity toolkit, including LongevityBench, Longevity-LLMs, and LongevityClaw, with collaborators in a Cell cover study, accelerating research and therapeutic development. That publication follows Insilico’s contemporaneous Nature Biotechnology paper, in which Rentosertib, the company’s most advanced AI-driven pipeline candidate, showed biological age reversal according to Phase IIa clinical data across six independent proteomic aging clocks.
Since 2014, Insilico has published more than 50 research papers on aging and longevity, aging biomarkers, therapeutic targets, and therapeutics implicated in aging, longevity, and disease.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma. AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, please visit www.insilico.com
SOURCE Insilico Medicine
